Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wanted to point out something here. Noticing the news today is saying they didn't meet the Delaware standards for approval due to the number of non-voting shares?
They have a bunch of shares sitting and not voted. 223.4 million shares held by shareholders only at 43.7%. RS was never going to have a chance.
It was just like many have calculated they never had enough shares to pass the RS. There are a lot of people simply didn't want them to get the yes vote. And the broker didn't automatically vote yes.
So it was clear major shareholders didn't want the RS to pass. We still need to see the 8K and the actual numbers of yes votes verse no votes.
They did file, but I agree with their assessment that they will continue to have issues meeting the requirement of NASDAQ.
Even if RS goes through, and they convert that remaining convertible into 40 million warrants. The price of the warrants aren't going to keep the share price from tanking. Warrant holders will want out and the shares will balloon and crash maybe not as hard as the convertible but the warrants will certainly be at a huge discount to market price as they have proposed the warrant price will likely be at the 1$ line to put in a floor post RS.
That's basically saying if RS goes through the SP will go to 1$ in time. That won't prevent market shares from trading below 1$ again. It's just setting the fixed price when the 40 million warrants are exercised. It only mean big profit for the warrant holders since they will likely be able to buy shares with the warrants at 1$ post RS and sell into the market as long as the SP is anything above 1$.
They will just go below 1$ again in due time as the warrants gets sold off for profit taking it down to around 1$ per share post RS. The shorting and potentially more offerings to raise funding will pretty much put us back where we started. The dilution business will continue.
Going to OTC they no longer need to be concerned with NASDAQ listing requirement. They can focus on getting new source of funding either new investor, M&A or partnership. If they fail miserably at that, it means they will need to file for BK protection because they are still in default with the convertible notes holders.
Going to OTC was expected. They have said on 8/21 filing if RS is a no, they will likely be delisted. So that's exactly what's going to happen as they apply for listing on OTC and transition take place on 9/21 or so.
This changes nothing. Hudson Bay, Ren, and Vanguard are all still in this. The company funding is still locked up and RS is still a no, and they are still maxed out at 500 million shares.
OCT news isn't surprising, it was expected. What we want to know is what happens next? How are they going to solve their funding issue?
Regardless of whether or not the BoD or CEO were considerate of the shareholders. They still face the same problem that they have no money left.
If they file BK at this point, it will raise a lot of alarms and serious investigations law suites will kick off if not already. All shareholders and even medias are investigating Delcath. Like I said, management would be foolish to go too far to mess with the public.
The million dollar question still remains. What are they going to do about funding? Apparently, no RS = no funding via the notes holders.
Assuming Hudson Bay or whoever held these convertible notes. They would be knocking on Delcath's doors too since they aren't getting paid for the remaining 13 million or so.
However, the notes holder have already made profit with the other 22 million sold into the market which caused the crash. Maybe they could careless.
Because the fear is causing sells and someone is happily loading up cheap !!
Exactly, they are being forced is the point here. No RS means they can't continue the dilution business as usual for the BoD and the institutions involved. The product will have to sell or they face BK. This it's not hard to see here.
The shareholders are not dumb either. Delcath will have to offer a better deal on restructuring the debt or get a partnership for new source of funding for anyone to vote yes on RS.
It's like a bad wife that spends all your money and not do anything in return for you. One day you take away that money and she would be without a choice and may end up actually do something for once lol.
Soon it will be clear to us. Short or long make your bets.
Yes, I have always knew they have about 15 million on their liabilities. And yes BK is pretty much the end of it all.
We're betting they sell before that happen because they are being forced. If they don't sell or partner up to bring funding they are done. That's the ultimate end. Between losing all assets to notes holders or taking any low balled offer the choice is pretty obvious. This is the time for any other company out there that wants the patents and the treatment no doubt about it.
Put yourself in the shoes of these management people. Their biggest concern is end of careers. RS, Sell, Merge, BK all of that is on the table as long as they can continue and not ended up unemployed.
This is apparent because they were pushing RS hard because that provides an immediate relieve to their going concerns.
If this was taken from them with a no vote. What comes down to is either sell, partnership or BK. So put your money where you think is appropriate. If you believe they will BK why not short like some people are doing it's likely to get reduced to nothing and short would win big.
On the other hand, if you belive they will find a solution before BK, go long while the shares are still cheap.
Gator the end goal of FDA approval is a good reason to support RS. But, you obviously knew what's happening currently with the financials.
FDA approval won't be until 2019 at the earliest because that's when their trials will be done according to the SPA agreement with the FDA. Now in the mean time we're looking at another 2 years of time minimal.
Now ask yourself this. What happened since last year end and this summer? The way Delcath was getting funding is reducing the stock from dollars to almost zero. You really think 2 more years and you'll still have any value left?
No way this management is going to be allowed to continue this horrific mismanagement. As some have said they are pretty much running it into the ground. So don't be delutional about getting FDA approval and maximize shareholder returns. You'll lose 100x over before you get anything back.
Why do you think majority voted NO and it was so hard for them to get that yes vote? This management is done, they have no business to continue running the company. As the recent CNA article puts it, they don't know how to run a company plain and simple.
Sell the company is the only real way to get anything for the investors. Not filing BK just so the notes holder takes a valuable asset. Not RS so they could offer 40 million warrants and continue to dilute the stock to nothing. No, none of that is the solution. The solution is to sell or get a partnership to run the show.
Yes N3, this CNA article and the 10k says exactly what I have been telling people that Delcath has no ability to market the product. They got EU approval but they don't know how to take advantage of the market.
Manufacturing and supply needs to be established and obviously marketing sales and advertisement. So they got something good but they have no idea what to do with it is what they are saying.
Why do you think they have anti takeover protection? These guys knows they got a good product which Roche and potentially others have approached them before. They knew they would be open to hostile takeover so it seems they aren't so dumb and that they have anti takeover protection.
Things gets interesting now because the funds that holds the convertible notes have the rights to the assets because Delcath obviously put up their asset to secure the funding which is common practice.
So if Delcath default on the obligations, the funds would have the rights to foreclose and take their assets pretty much results in a BK.
So now is the critical time as we have always been discussing is they trying to make a deal go through to save themselves with whoever was interested and made an offer. Otherwise, they need new investors to bail them out. And we all know if they can't pull that off, BK is likely because they are in default with the convertible holders if they can't get RS to pass.
So it becomes clear, this management team doesn't know what they are doing. lol. That's why shareholders are pushing them to just sell it and be done. They have done enough at this company and it's time for the close of the chapter. BO, merger or BK. They would be wise to accept even a low balled offer, otherwise, the notes holders will take it all from them.
@The_Janitor, while there have been a lot of information thrown around in recent months including media articles too. But, when you do the DD yourself and you ended up discovering half of that information is wrong or made up. Just people trying to influence the trade for money of course.
So as they say always do your own DD. First, look at the value of Chemosat and what the science trials reported in the past.
Look at the obvious facts that the company is having a very hard time getting a yes vote on RS. Look at funds holding millions of shares and why company is so quiet about anything lately. These are hard facts.
Things like they were listed as participant in EU medical conference which they didn't tell anyone. In the past, they have always listed their up coming events on the website. And of course, the expected interim safety results of the phase 3 focused trial what happen to that?
There was a focused phase 3 they started some times back and it won't complete until 2019. They have interim safety results that were expecting to report 2H of 2017. So we're looking at anywhere between June and December. But, you would think they have that data by now.
So that's the other hint that they might be in quiet period where they aren't going to report anything on the trials.
Some of us are betting on the partnership or M&A deal because apparently some funds have a pretty good sized holding.
While some might say they brought just so they could vote yes. But, if you look at the filing date, both Hudson and Ren and Vanguard increases weren't in July. They were filed in mid - late August.
Now, we know the vote cut off date was holders on or before 7/13. Therefore, it is unlikely Hudson, Ren, and Vanguard bought to influence the votes.
Perhaps if they participated in the offering of the convertible preferred. Those shares would be eligible for voting rights. So when you look at all these fine details, you start to see something else going on here.
Why is Hudson, Ren, and Vanguard still holding a good sized shares? Hudson 25 million, Ren 10 million and I think Vanguard inreased to 1.2 million recently.
The quiet mode and institutional ownership typically points to some sort of deal in the making. Even if Delcath just able to renegotiate the convertible debt and get new source of funding, it's big news.
Yes Sagemaker1, that was my original prediction last Friday that we won't hear any news until Wednesday AH.
We're thinking they did that for a purpose. Last week we discovered Delacth was registered for a large EU medical conference for the days between 9/8 - 9/12 which the conference ends today. Delcath Systems was a registered participant.
There was also a rumor they are to fly to Basel in Switzerland Wednesday which is tomorrow where Roche HQ is located.
Obviously there was another rumor saying they are finalizing a deal in NYC. There is obvious conflict in these two rumors. Just the former is more believable.
Unfortunately, we have no way of confirming whether or not Jenny is in EU this week unless you happen to see her at the convention.
Yeah, the unexpected usually can happen. When everyone was expecting a big run, maybe we get to something like 16 - 20 and it ended up disappointing.
In any case, if RS is a no, Delcath is in a real tight corner they need a solution fast before they are forced having to stop all trials and development including pay cut because last Q the reported 1.8 million cash left.
Management might not like it but they have no choice. If they can't finalize a deal, they will have to cut back on all spending. We haven't heard anything what so ever from the company.
That's why I feel comfortable they won't drop a BK news on us like that simply because it's illogical.
So we should hear about RS news or some sort of partnership BO deal. Otherwise, they will come out and say they will be cutting all expense to prevent going into negatives. Until then I'm not worried about BK.
I think that's what it smells like right now. They aren't coming out saying they have no funding and may need to cut all spending going forward.
They are obligated to inform investors if the company is in danger of BK and that they are not going to be able to service the debt.
If they simply file BK in quiet mode, they are looking at major lawsuits. Lawyers will be all over them.
Really the only debt they have are the 12.6 million convertibles shown under their liabilities. They owe some 990k on account payable probably to suppliers, and they have 1.8 million cash in hand.
So if RS is a no, they should have come out saying they are unable to access the restricted funding and will be forced to cut back on all spending and potentially file for BK protection. It's just odd they aren't saying anything including the RS vote result. Something don't add up here.
Possibly. Under normal circumstances they would be breaking the law. But, if there was a request or some sort of non disclosure filed with SEC they can legally hold back the news.
So if we don't hear anything by tomorrow AH, I think you are right. They likely have something big going on that allows them to not PR the vote result. In case like this, no news is actually great news.
I am not an expert in legals so maybe someone with experience can look that up. I do know that if a trial result or new product is part of a negotiation, the suitor and the company usually sign some sort of confidential non disclosure agreement which typically results in the company being quiet about anything that's related to the product during negotiation periods.
But, can an RS vote result be considered something that affect the negotiation in some way that they withhold the info? We know that RS result can cause fluctuation in share price and it would be hard to make a deal but Delcath is not valued based on market cap unless the suitor is intending on buying shares.
They just seems to be taking sweet time on pretty much all news.
Yeah, nothing but rumor, last time they said Delcath is to meet Roche in Basel. Just trying to pump when no RS is announced to make a run which isn't a bad thing :)
Yeah, the market cap hasn't changed too much. It's amazing what convertible debt can do to a stock in such a short period of time. It's almost a guaranteed short when you see a company take out such finance deal. In any case, it's unbelievable they agree to the deal back then.
They obviously realized the mistake and tried to renegotiate and extinguish the convertibles but a little too late.
Yeah, Roche are into Immuno-Oncology research. They are pretty big on cancer treatments. If Chemosat has that billion dollar market potential, they may benefit from partnering with Delcath and pick up the trial expenses and FDA approval process. As we know the second generation filters have demonstrated less side effect and improved safety. Plus they can expand that on few other indications.
Mean while, Roche can rapidly expand Chemosat treatment centers across EU and put in some advertisement campaigns especially when insurance is covering the treatment. Revenue can start rolling in pretty quickly in EU market.
A partnership is a win win situation as I've suggested before. Because a partnership doesn't result in a take over and management losing their jobs. So that brings not only funding and development support it's also job security.
On the other hand, investors gets rewarded too. This is by far the best out come anyone could hope for. They can ask for an RS after the deal announcement, it would be much easier to get a yes vote with some decent terms proposed to shareholders. They would almost guarantee to get the yes vote.
So the choice is obvious between BK, BO, TO, or partnership. Hoping they get something out of EU visit this week. As soon as they agree to some sort of deal, they can PR it and NASDAQ may have a reason to grant them the extension they appealed for.
So, it's make or break if you're holding shares here lol.
I think the risk is still there. They are being pushed way too rushed. One would think they would be planning an exit since the first vote no started from before June. They have a good 3 month time to look for a potential deal to bail them out. Otherwise, the risk is still there they are in debt and no money, they may file chapter 11.
The delay on the news is likely because they knew RS vote is a no and they are trying to figure out how to address the public and figure out what's the next step.
BO or not would come sooner than later because like I said, they can't wait. If no RS and no funding they would be forced to stop all operations and cut spending drastically. So if there are deals on the table and one being finalized, it should be soon. I agree there is probably more than one interested party which is a good thing.
In any case, they can't hold off RS vote results forever so we should at least see that news this week. Let us hope they didn't waste a trip to EU this week. Would be cool if someone leaked her flight itinerary lol
Agree, this was a 3$ stock last year. One bad finance deal and it all went south very quick. As you puts it, being run into the ground.
No doubt a whole lot of people are holding this long. That's why it's been so difficult for them to get a yes vote. If everyone sold and left, it would have been easy for them to get the votes.
The past trials have shown significant benefits in both progression free and overall survival. Science side is pretty solid or one might call it impressive. I just can't believe this kind of treatment would be sold for 10 cents a share in BK sales, just doesn't make any sense.
If Delcath were to put it up for sales, there would be more than one interested parties. That's what the current shareholders are pushing for with the no vote.
Here is a good article published by a third part and not from Delcath. There are more sources out there. I know it's a wall of text but you want to make good investment choices, you got to put in the work and time right?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126197/
Feel free to share other findings if you come across something that supports the case the Chemosat is an effective treatment.
Agree, the key is that Chemosat has value, if competitions bid on the treatment and patents it would be a different story.
The thing with Delcath is that people have different views of Chemosat treatment. Some seems to think it has little value due to the fact that they generated little revenue in EU and that US approval is taking forever.
Some looks at it purely based on scientific results because we all know Delcath is too small to really market anything effective. But, the said treatment with EU approval under the right owner can be a different story.
So the treatment is targeting an area that doesn't have a standard of care and that it has an unmet medical needs. Keep in mind Chemosat has been approved in EU and Australia. US approval might be couple years away but, it should not be an issue once they proved safety has been improved in the on going and new phase 3 trials as it was already proven in EU with two centers reach 100 treatments.
FDA would not have allowed two more phase 3 if they don't think the treatment was effective and that it benefited the patients. Matter fact, FDA agreed to Delcath trial design and ok that with potential approval upon successful trial.
No doubt big names like Roche, Bristol Myers, or Novartis is well aware of Delcath and what they are doing. If the science side was a big failure that would be a different story. But, not according to their press release and past and existing trials they are extending patient life by a significant amount of time. Unless they are lying to the public that should not be over looked.
I highly suggest you guys go a read about the Chemosat trial results and what they are reporting. It will give you an idea how effective the treatment was compare to other treatments currently out there.
A lot of people have brought up the point that management has little incentive to get a good deal and bring shareholder value. Look at it this way.
When management runs Delcath, they need these institutions and people in finance world to help them out from time to time in order to get funding right. But, when if these people said no? As we have seen with the recent proposal they renegotiated with the debt holders. And, it doesn't looks like these financial people are giving them much choice here. Otherwise, we would have hear them restructured the debt and funding would be no longer an issue even if RS don't pass. So, it is clear to me these finance people aren't interested in bailing them out of the situation.
Secondly, we know public owns about 80% of the company and RS vote will be a tough one. So what this creates is a forced sell of the company. Because, if the financial groups won't bail them out, and they can't get an RS from shareholders, naturally they would need to find other means to exit.
You think any billion dollar investor would come and pay off their debt and invest in them at this point? I think not, no body in their right mind would trust the current management unless they plan to reorganize from top down. Even so, seeing the treatment through two phase 3 and FDA approval is expensive. I doubt anyone would take that much risk.
So yes, the options are likely limited with funding for Delcath. And, that's why a lot of people are betting on a M&A or some sort of partnership because management don't have much options left. And, Chemosat is not worthless as we know at least one party have made an offer in the past.
So the logical plan is of course to sell if we get any pops, but I am holding a core short term at least for the next few months for something potentially more.
It doesn't say if short hold over night. We only see the volume but the chart is basically saying short during the day but cover before close. Just like if you were to sell at open, then buy back at bottom during the day and repeat tomorrow.
Just day trading Toro, they don't hold over night. That's why you see the dip in the morning then it recover at close because they have made the money and will buy back and cover. New can come AH so it's too risky to hold over night.
You would think when they are negotiating, other stuff tends to fall off the priority list. They are probably very busy including the trip in EU this week. Frankly, when RS is a no, they would need help. They need somebody to bail them out fast on the funding issue since the funds are restricted when they have no more shares to satisfy the conversion. Don't forget they are out of money by September.
Apparently they have been negotiating with the debt holders too and the best they could come up with was 40 million warrants in exchange for convertible shares if RS passes. This deal won't do anything unless RS is a yes. The debt holders needs to be paid one way or another. There is no escaping that.
Hope they be able to finalize a deal soon because if RS don't pass they still have funding issue in September and they need cash to go on at least for a month or two. Assuming there are more than one party interested, it should be ok deal. Even though low balled but still it might be a decent one if competitions bid on it.
Assuming Roche did big on it, Roche competitor would know about it when rumors goes around.
As I said Friday, we probably have another day of two for quick trades same pattern. We may not hear anything until Wednesday. I think they are focused in EU this week, and as long as they don't wait too long to file the vote results. It be interesting if we hear any surprise news not related to RS vote.
If they knew RS is a no, they have more pressing issues than counting RS votes.
@ Sam, SEC regulations requires they file schedule 13 form for owning more than 5% voting right of the company. Hudson can't legally hide their ownership. So the ownership is accurate otherwise, they are breaking the law. I doubt they do so openly. Plus you could look at Hudson's own filings too.
Plus Delcath is maxed out at 500 million, so they can't convert anymore. However, the preferred shares still has voting power equal to the shares converted. And, according to these SEC filings they couldn't vote with their 25 million shares purchased in August. They may vote if they held the preferred shares offered earlier this year.
@H2004, it was concerning though and I too was wondering who advised them to take a financial deal like this last year.
A CEO that doesn't know the consequence of convertible debt simply blows my mind. Was it truly that bad they couldn't find better fiance last year? I doubt it.
There are many ways to raise capital including selling ATM, and there are many far better ways than convertibles. It just makes you think if all this was staged and done on purpose.
But, the funny thing was that this management seems like a victim rather than the mastermind. There are a lot of failed companies out there new and young companies swimming in the water of sharks.
In any case, I hope management find a good buyer and exit. They have done enough at the helm of this company. Frankly, they have done a poor job.
Maybe Hudson Bay is simply trying to avoid possible SEC investigation because the SEC highly likely to be watching this one especially with all the reporting filed with SEC by shareholders. They would need to be very careful here.
If they did buy prior to 7/13 and then voted yes while holding convertible debt with these new terms it would be too obvious for SEC investigation, and they can and will get fine by the SEC.
Maybe they bought in only because they expect a no on RS and potential BO or partnership. Either way, Hudson would be dumb to risk 25 million shares if RS was to pass. They should have been sold out like Aryton Captial, but they didn't sell.
Funny how some ST users are shaking and afraid to hold over a weekend. What do you think the fund manager at Hundson Bay is thinking when he's got 25 million shares long?
Correct, SSR is none factor that we should not be concerned with it. Shorts will short trade will go on just like any other day.
It's just a promotional tactic to get into people's minds making them think no one can short the stock. Simply take a look at the volumes sold short on SSR days and you got your answer.
Like I said until news we probably won't move much but just usual trading activity. You can take advantage of it to gain more shares if you know what you're doing.
The only reason I am holding long is because of Hudson Bay and Ren. Institutions holds shares for a reason. Even though they are probably up to no good but chances are they are expecting a favorable outcome for their investment.
One thing is clear is that management have been forced into a desperate situation. One they face a balance sheet problem, and two they can't raise more funding.
Why do you think they run over to EU? Yes, they are trying to get some sort of deal to save the company more so save themselves. That's what we're betting on here.
You're not getting the pictures here. Management won't take a BO yes that is correct, it's not in their best interest we know that.
But you're not getting the fact they are being forced. Without funding, and because the stock is at 0.12 and they can't offer anymore shares they have no options. The institutions holds the debt, it means Delcath is at their mercy.
If RS fails, they have no choice but to sell. Or they will need the institutions to bail them out. Do you really think the tutes wants to bail them out?
Last the tutes negotiated with Delcath on the conditions that RS pass they would be awarded 40 million warrants. Delcath is being ripped off by the tutes and caught with their pants down if you don't see that.
If RS is a no, they would rather Delcath sell the company as they are holding millions of shares. Don't you get why Hudson Bay and Ren and why they are holding combined 35 million shares as well as Vanguard tripling their positions?
As I said before, the funds wins no matter what.
Pretty much, maybe HB or Ayrton Captial did them in on purpose ever thought of that? Management got suckered into taking that 35 million convertible deal last year, and then the institutions took full advantage of the market and crash the SP so hard so they could benefit from all the action of the up and downs raking in potentially hundreds of millions. These funds have been fined by SEC before for taking the offering then short the stock after. 3$ to 0.02 is a big deal ok.
Last June a run to 0.36 made many millions no doubt on both short and long. That's what I think happened. The true masterminds are the institutions hedge funds playing this company.
And guess what, they hold the debt in hand and yet again trying to take advantage of the desperation of this management by proposing terms to amend the convertible on the conditions that RS pass and they get 40 million warrants at below market price with a 1$ floor. Big dollars to them again. I see through this kind of stuff and it happens all too often if a company management is not careful.
The funds are the ones screwing Delcath and the shareholders. They hold millions of share if BO were forced and guess what they make big dollars once again.
Either RS or no, the funds win. These guys are some times referred to as loan sharks for a reason. It's the ugly side of the business world. No matter how things turns out the funds win even in a BK scenario, they take the asset and sell. Zero loses for the funds and zero risks.
Management made a costly mistake and it may cost their jobs and the loses of the long term shareholders as well as valuable technology.
My prediction is we might have yet another day or two next week for some trade to get more shares at the 0.12 - 0.14 range. It may edge up to 0.15-0.16. Although news could be AH today. In any case, it is inevitable.
For the golden parachute, they need not be concerned. After they announce a deal, the SP will shoot up and then they can ask for another RS and it should pass which allow them to close the deal maybe few months later and still exit with stock options upon deal close.
Most investors expect management to deliver first before they get paid. Simple as that. No RS unless we get a deal done first. But you are right, they are wide open for a hostile take over.
They can't prevent someone from buying up 51% of the company shares. 250 million share is 50%. Roche could easily approach the shareholders and offer. Many probably sell for 30 cents which only cost them about 75 million to get 50% shares. Not to mention if they offer more say at 50 cents for 125 million. Tell me you wouldn't sell for 50 cents. Most us will sell for 50 cents lol.
In a way Delcath is like fat piece of meat waiting to be eaten.
Yes, that's what we have been seeing is that they have been rather quiet lately.
Let see if our predictions are right. They went over to EU only for one reason to try and sell the company or seek partnership, and then, they meet with Roche who have been in talks. Roche made an offer back in 2010 they would be interested.
The deal might come few months later or it could be soon if it's Roche. Roche knows their financial situation, there is no hiding it. It's public knowledge since it's a public company. Roche knows every bit we know and possibly more.
So Delcath can't hide anything from Roche and they knew RS is a no. But Delcath can still try and delay the news because RS vote result is not official until they filed with SEC. So the vote concluded 9/7 5PM the latest they can delay it is until next Wednesday AH.
If we see no news next Monday and Tuesday, you can bet your money it will be Wednesday AH and that it is likely like you say, they don't want voting result news out while negotiating with Roche.
Let see what happens next week.
Sam, that's what makes things interesting. I personally love to do DD and try to find out what's really happening behind a company.
I am of course not right all the time, but I am pretty good at digging up things and make a prediction.
As to the share price, it should not run anywhere until news. Just traders doing their thing and people accumulating as well as less informed selling. You name it, all sort of people in the market.
But, all of that is not important to me. I only care if they get a M&A or partnership as the result of No RS vote.
Right now, RS is looking like a definite no and they are in EU. That's all that matters.
Here it is. They are attending the 2017 ESMO in Spain that's going on Sep 8 - Sep 12. Look at the industry participants. Delcath Systems Limited was listed as registered participant.
http://www.esmo.org/Conferences/ESMO-2017-Congress/Industry-Participation
So there is a chance they do fly to Roche HQ on Wednesday next week at the end of the conference in Spain according to the rumor.
This is a big big event in EU and we heard nothing about it? Something is up big behind the scenes.
In the Q2 earnings report they have stated interim safety results of the focused phase 3 is on track but we heard nothing of it either.
Matter of fact we heard nothing but RS talk and they even delayed the Germany celebration.
I think their intention is to try and get a EU partner. That's why they are attending the conference to put the words out so that they get better offers while Roche is also in talk.
If they were only focused on RS then why bother attending the medical conference? They will be presenting to a lot of EU folks and a major opportunity to gain exposure to whatever they are trying to say.
Interesting rumor and connections. Now, this is of course just a rumor but what's interesting is that they are saying Roche plans to meet with Delcath in Basel head quarter next Wednesday which is in Switzerland. Now, Delcath happens to be attending a conference in Spain this week. So they visit Roche HQ next week is possible.
https://wallstreetwhispers.blogspot.ca/2017/09/roche-viewing-european-success-of.html
I have always thought an EU company would want to pick up Delcath since they have full approval in EU and showing actual practices in both UK and Germany plus several other centers through out EU. The combined EU and US market is no joke.
I wonder what they are doing in Spain this week other than the conference. Typically, the company would PR if they are going to a major medical conference right? We heard nothing of this one they are attending in EU. I didn't save the link but a while back someone found them listed as a presenter on one of the medical conference going on in Spain right now. Trying to find that link again.
Yeah, it takes a lot to hold this thing for as long as some of us have lol. And we can certainly lose it all.
That's why a lot of people will only trade the day and rarely hold more than a day. I mean just buying at 0.10 and selling at 0.14 is major profit already. I have been trading between these up and downs while keeping a core. Just too good to pass up on the high risk high reward chance we got here.
Agree, it's not the time to run up yet.
Lol, I think probably 90% or more of the current investors would agree. They had their chances with 2 1 for 16 RS already and boy they really screw it up this time.
They have fooled investors 2x, I don't think people will allow it to continue.
The pattern is pretty easily seen here. It always pops then gets short or sold down and cover end of the day. I've already increased my shares yesterday and again this morning easily sold at 0.14 and buy back at some where around 0.12-0.13
Not sure what you mean but if no RS the convertible notes cannot be satisfied because they can't issue anymore shares. The remaining convertible is as good as a void check. They can't get any money that way.